Back to results
US 2018/0133314 A1Published application
Detection of fgfr2
AssigneeDaiichi Sankyo Company, Limited
InventorsChigusa YOSHIMURA, Reimi KAWAIDA, Kokichi HONDA
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
Claims46
A monoclonal antibody or an antigen binding fragment thereof which has the following properties (i) to (iii):
- (i) specifically binds to non-denatured human fibroblast growth factor receptor 2 (hFGFR2) IIIc;
- (ii) specifically binds to none of the following:
- non-denatured human fibroblast growth factor receptor 1 (hFGFR1);
- non-denatured human fibroblast growth factor receptor 3 (hFGFR3);
- and non-denatured human fibroblast growth factor receptor 4 (hFGFR4);
- and
- (iii) specifically binds to denatured hFGFR2 IIIc in a preparation fixed in formalin.
4 more elements
23-24. (canceled)
41-42. (canceled)
(canceled)
Dependencies are inferred from the claim text.